Sarepta Investors Sue In Delaware Over Drug Risk Disclosures
A Sarepta Therapeutics Inc. investor launched a federal suit in Delaware Tuesday against the drug developer's board and top officers, seeking damages on behalf of the business for allegedly costly failures...To view the full article, register now.
Already a subscriber? Click here to view full article